Year One of the New Biomarker : A Drug Pipeline Primed for Results
Driven by the new biomarker ( the so-called alphasynuclein seeding amplification assay , or aSyn-SAA ), and steps taken toward the biological staging of Parkinson ’ s disease , the momentum in Parkinson ’ s research is enormous and growing . This great leap forward is unfolding alongside the most robust pipeline of therapeutics in history , powered in no small part by The Michael J . Fox Foundation ’ s strategic research agenda over two decades .
4